Details of Disease

General Information of Disease (ID: DISG0EIG)

• Disease Name: Acute lung injury
• Disease Class: NB32: Intrathoracic organs injury
• Definition: A condition of lung damage that is characterized by bilateral pulmonary infiltrates (pulmonary edema) rich in neutrophils, and in the absence of clinical heart failure. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
• Disease Hierarchy:
  DISBV50J: Acute disease
  DIS1LT8E: Lung disease
  DISKB4RK: Injury
  DISG0EIG: Acute lung injury
• ICD Code:
  ICD-11: ICD-11: NB32.3
  ICD-10: ICD-10: S27.3
  ICD-9: ICD-9: 518
  Expand ICD-11: 'NB32.3Z
  Expand ICD-9: 518

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Calfactant	DM7N16W	Approved	NA	[1]
Tezacaftor and ivacaftor	DMY62FC	Approved	NA	[2]
Sivelestat sodium hydrate	DMOSJD0	Phase 4	Small molecular drug	[3]

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FP-1201	DM823WQ	Phase 3	NA	[4]
L-citrulline	DMT4K0Z	Phase 3	Small molecular drug	[5]
Aviptadil	DMJS42H	Phase 2/3	NA	[6]
Dilmapimod	DMBYJ92	Phase 2	Small molecular drug	[7]
Drug 2862277	DM8WU3O	Phase 2	Antibody	[8]
DX-890	DMBFZET	Phase 2	NA	[9]
GSK2586881	DMU5EVR	Phase 2	NA	[10]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ZD-8321	DMBSXPJ	Discontinued in Phase 2	NA	[11]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DK-0141	DMS6GBG	Investigative	NA	[6]
Recombinant Slit-2-D1-D2-Fc	DMI9DTZ	Investigative	NA	[6]
STX-200	DMWM7SP	Investigative	NA	[6]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [3] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [4] Clinical pipeline report, company report or official report of Faron Pharmaceuticals.
• [5] ClinicalTrials.gov (NCT02891837) L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects. U.S. National Institutes of Health.
• [6] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7815).
• [8] ClinicalTrials.gov (NCT02221037) Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT00455767) Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT01597635) The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury. U.S. National Institutes of Health.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007250)
• [12] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.